User Fee Waivers, Reductions, and Refunds for Drug and Biological Products
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
September 27, 2011
May 6, 2020
ff74c3d1-95d4-4808-9bba-25a26706e7e4
Related Documents
Expedited Programs for Serious Conditions | Drugs and Biologics
Guidance DocumentMay 30, 2014Center for Drug Evaluation and Research
Safety Labeling Changes -- Implementation of Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act
Guidance DocumentJuly 30, 2013Center for Drug Evaluation and Research
Dear Health Care Provider Letters: Improving Communication of Important Safety Information
Guidance DocumentJanuary 2, 2014Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Stay ahead of FDA enforcement
New KeyPedia insights, webinars, and regulatory analysis — straight to your inbox. Unsubscribe anytime.